Patients with overweight or obesity who used maridebart cafraglutide experienced significant weight loss at 1 year, according ...

BioSpace recaps 2024’s top venture capital rounds in biopharma, from Xaira Therapeutics’ blockbuster $1B raise to ...

The series A fundraising is the biggest ever for a European biotech firm, according to the data provider PitchBook.

Adults with type 2 diabetes using a GLP-1 receptor agonist have a similar risk for developing thyroid cancer as those using a ...

The following is a summary of “Treatment of Hypothalamic Obesity With GLP-1 Analogs,” published in the November 2024 issue of Endocrinology by Dimitri and Roth. Damage to hypothalamic nuclei or ...

Cancer researchers found that patients on GLP-1s had significant risk reductions for 10 of 13 obesity-associated cancers.

For patients with diabetes undergoing a surgical procedure, an active perioperative glucagon-like peptide-1 receptor agonist ...

Fresh from a $400 million series A round, Kailera Therapeutics has shown off phase 2 data on an obesity candidate it believes ...

On Jan. 1, North Dakota became the first state in the country where access to drugs like Wegovy is part of the EHB package. About 55,293 of North Dakota's 784,000 residents had coverage through fully ...

Eli Lilly's experimental weight loss drug, retatrutide, has demonstrated encouraging results in helping obese adults lose weight.

McDonald's shares underperformed in 2024, likely due to the rise of GLP-1 medications. Learn why MCD stock is a Sell.

With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.